3,460
Participants
Start Date
September 8, 2020
Primary Completion Date
December 30, 2022
Study Completion Date
December 30, 2022
Enoxaparin
Prophylactic enoxaparin (40 mg SC QD; 30 mg SC QD for CrCl \<30 mL/min) Full-dose enoxaparin (1 mg/kg SC Q12h; 1 mg/kg SC QD for CrCl \<30 mL/min)
Apixaban
(5 mg Q12h; 2.5 mg Q12h for patients with at least two of three of age ≥80 years, weight ≤60 kg or serum creatinine ≥1.5 mg/dL)
Icahn School of Medicine at Mount Sinai, New York
Instituto do Coração - INCOR, São Paulo
Instituto Prevent Senior - IPS, São Paulo
Clínica de la Costa, Barranquilla
Clínica Shaio, Bogotá
Fundación Cardioinfantil, Bogotá
Fundacion Oftalmológica de Santander - Foscal, Bucaramanga
CardioVid, Medellín
Centro Médico Imbanaco, Santiago de Cali
Eternal Heart Care Centre and Research Ins Pvt Ltd., Jaipur
Jaipur National University, Jaipur
Sawai Mann Singh Hospital, Jaipur
Jaslok Hospital & Research Center, Mumbai
Saifee Hospital, Mumbai
Sengupta Hospital & Research Institute, Nagpur
D Y Patil University School of Medicine & D Y Patil Hospital, Navi Mumbai
Hospital Cardiológica Aguascalientes, Aguascalientes
Centro Médico Nacional 20 de Noviembre, Mexico City
Christus Muguerza Hospital Alta Especialidad, Monterrey
Centro de Estudios Clinicos de Querétaro S.C., Querétaro City
Centro Medico Hospital del Prado, Tijuana
Valentin Fuster
OTHER